Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x100px
Document › Details

AB Sciex (d/b/a Sciex). (4/1/20). "Press Release: Sciex Debuts Breakthrough Method for Gene Therapies". Framingham, MA.

Organisations Organisation AB Sciex (Danaher, Framingham, MA)
  Group Danaher (Group)
  Organisation 2 Pall Biotech
  Group Danaher (Group)
Product Product capillary electrophoresis (CE)
Persons Person Krishnan, Mani (Danaher 202004 VP Global Biopharma + Capillary Electrophoresis at Sciex)
  Person 2 VanZandt, Lulu (Danaher 201807 Brand, Public Relations + Social Media at Sciex)

Robust high-resolution determination of full, partial and empty capsid ratios for adeno-associated virus analysis

SCIEX, a global leader in life science analytical technologies, launched an exciting new method for streamlining and improving the production of gene therapies. This innovative capillary electrophoretic method addresses a key customer challenge by analyzing AAVs to determine whether the therapeutic transgene payload has been successfully incorporated into the AAV vector product.

During the manufacturing of AAV vectors, capsids containing the full payload of transgenes are produced along with a high percentage of capsids that might not incorporate any of the transgenes (empty), or contain fragments of the transgene (partial). The presence of these impurities could increase immunogenicity or inhibit transduction of full capsids by competing for vector binding sites on cells.

“Successful incorporation of the transgene is critical for the efficacy and safety of gene therapies,” said Mani Krishnan, Vice President of Global Biopharma and Capillary Electrophoresis at SCIEX. “The ability to quickly determine capsid payload using small sample amounts will help drug developers speed their time to market, as well as deliver a safe and effective product.”

This new analytical method is able to detect with great precision whether the AAV capsids are full, partially full or empty. Key attributes include:

> A platform method that can be optimized for the separation of full, empty and partial capsids in AAV samples across multiple serotypes

> High resolving power: separating full and empty AAVs with very small isoelectric point (pI) differences of = 0.1 pH unit

> Rapid analysis time: less than 1 hour per sample

“For gene therapy developers, time to market is critical. Unlike other classes of drugs, where a disease can be treated by multiple medications, gene therapeutics cure diseases by targeting specific genes. The one who gets there first wins. There is no second place,” says Rachel Legmann, PhD, Director, Technical Consultancy - Gene Therapy and Viral Vectors at Pall Biotech and SCIEX research partner. “That’s why scientists in biopharma are driven to develop a robust manufacturing process. But there’s a lack of reliable and reproducible methods to consistently produce AAV-based gene therapies, which means there is a lot of risk to get these therapies to market.”

“This new method offers a key to improving and streamlining the development and production process for AAV-based therapeutics,” continued Dr. Legmann. “When you have the right analytics for the entire in-process samples as well as release testing, you can navigate the upstream and downstream process to develop better quality and safer products – helping to reduce the cost of the manufacture.”


SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. We have led the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed groundbreaking technologies and solutions that influence life-changing research and outcomes.

Today, as part of the Danaher family of global life science and technology innovators, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers are able to quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer.

That’s why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.

For more information, visit

Let’s connect: Twitter, LinkedIn, Facebook, and Instagram.

Advances in human wellness depend on the power of precise science.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries.

© 2020 DH Tech. Dev. Pte. Ltd. RUO-MKT-12-11288-A

Contact Information

Lulu VanZandt
Manager, Brand, Public Relations and Social Media, SCIEX
+1 (508) 383-7163
M: +1 (508) 782-9484

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Danaher (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group Asia Bio Partnering Forum 2024 Singapore 650x300px

» top